Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/12/22 21:29:03」(JST)
wiki en
| Systematic (IUPAC) name | |
|---|---|
| (+)-(R)-3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole | |
| Clinical data | |
| Trade names | Frova |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a604013 |
| Pregnancy cat. | B3 (AU) C (US) |
| Legal status | Prescription only |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | 20–30% |
| Metabolism | Hepatic |
| Half-life | 26 hours |
| Excretion | Renal |
| Identifiers | |
| CAS number | 158930-17-7 N |
| ATC code | N02CC07 |
| PubChem | CID 77992 |
| DrugBank | DB00998 |
| ChemSpider | 70378 Y |
| UNII | H82Q2D5WA7 Y |
| KEGG | D07997 N |
| ChEMBL | CHEMBL1279 Y |
| Synonyms | 6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide (6R)-6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide |
| Chemical data | |
| Formula | C14H17N3O |
| Mol. mass | 243.304 g/mol |
|
SMILES
|
|
|
InChI
|
|
| N (what is this?) (verify) | |
Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1]
Contents
- 1 Pharmacology
- 2 Mechanism of action
- 3 Adverse effects
- 4 Contraindications
- 5 US licensing
- 6 References
- 7 External links
Pharmacology[edit]
Frovatriptan inhibits excessive dilation of arteries that supply blood to the head. It is available as 2.5 mg tablets.
Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.
Mechanism of action[edit]
Frovatriptan is a 5HT receptor agonist, with high affinity for the 5-HT1B/1D receptors. It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites.
Adverse effects[edit]
Serious but rare cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.
Contraindications[edit]
Frovatriptan should not be given to patients with:
- Ischemic heart disease
- Cerebrovascular syndrome
- Peripheral vascular disease
- Uncontrolled hypertension
- Hemiplegic or basilar migraine
US licensing[edit]
Frovatriptan is available only by prescription in the United States, and Canada where a secondary New Drug Approval (sNDA) was filed in July 2006,[2] and which is currently pending. The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM).
References[edit]
- ^ "Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28.
- ^ "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. 07/2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28. Check date values in:
|date=(help)
External links[edit]
- Frova (manufacturer's website)
- Frovatriptan Succinate (patient information)
- FDA labeling
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 成人における片頭痛の急性期治療 acute treatment of migraine in adults
- 2. エストロゲン関連片頭痛 estrogen associated migraine
- 3. 原発性頭痛 hypnic headache
- 4. 群発頭痛：治療および予後 cluster headache treatment and prognosis
- 5. 性行為に伴う一次性頭痛 primary headache associated with sexual activity
English Journal
- Frovatriptan: a review of its use in the acute treatment of migraine.
- Sanford M.SourceAdis, Auckland, New Zealand.
- CNS drugs.CNS Drugs.2012 Sep 1;26(9):791-811. doi: 10.2165/11209380-000000000-00000.
- Frovatriptan (Migard®; Frova®) is an orally administered triptan approved for the acute treatment of adults with migraine, with or without aura. This article reviews the pharmacology of frovatriptan, focusing on its efficacy and tolerability. The precise mechanism of action of frovatriptan is unkn
- PMID 22900951
- Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study.
- Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, Savi L, Pini LA, Sances G, Santoro P, Zanchin G, Omboni S, Ferrari MD, Fierro B, Brighina F.SourceClinica Neurologica, Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy.
- The journal of headache and pain.J Headache Pain.2012 Jul;13(5):401-6. Epub 2012 May 17.
- The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or alm
- PMID 22592864
Japanese Journal
- Chiral separation of Frovatriptan isomers by HPLC using amylose based chiral stationary phase
- KHAN Muzaffar,VISWANATHAN Balaji,RAO D. Sreenivas,REDDY Rajasekhar
- Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 846(1), 119-123, 2007-02-01
- NAID 10025790490
Related Links
- 企業系リソース (薬価情報含む) フロバトリプタン - QLifeお薬検索 - QLife. Inc. フロバトリプタン - 医薬品情報・検索 イ－ファ－マ - Allied Medical Associates Co., Ltd. 管理系リソース frovatriptan - 規制物質法(CSA) - DEA, アメリカ合衆国
- Frovatriptan is a headache medicine that narrows blood vessels around the brain. Frovatriptan also reduces substances in the body that can trigger headache pain, nausea, sensitivity to light and sound, and other migraine symptoms.
Related Pictures
★リンクテーブル★
| リンク元 | 「フロバトリプタン」 |
「フロバトリプタン」
-frovatriptan